Navigation Links
Micell Technologies' Rapid Absorption Polymer DES System to be Presented at CRT 2009
Date:3/4/2009

RALEIGH, N.C., March 4 /PRNewswire/ -- Micell Technologies announced today that David E. Kandzari, MD, will present "The Micell Rapid Absorption Polymer DES System" during the Cardiovascular Research Technologies (CRT) meeting in Washington, DC, on March 5, 2009. MiStent(TM), a Drug-Eluting Stent (DES) in pre-clinical studies, utilizes a bioasorbable polymer coating that delivers the potential benefits of the drug during the healing process. The proprietary formulation allows the polymer to be absorbed concurrent with the drug delivery rather than sequentially like other absorbable DES coatings. This allows both the polymer and drug to be eliminated within 90 days and provides the potential for improved patient benefits.

"The Micell DES technology is exciting because it is the first of a new generation of stents being developed to precisely deliver a drug while safely eliminating the polymer faster than any other bioabsorbable coating that is commercially available," said Kandzari. "The unique formulation that allows the polymer to be absorbed at the same time that the drug is being delivered offers the therapeutic benefits of a drug-eluting stent, while quickly transforming itself to the safety profile of a bare metal stent."

Earlier this year, Micell obtained the rights to a CE marked cobalt chromium stent to use as its platform for its proprietary coating. Arthur J. Benvenuto, Chairman and Chief Executive Officer of Micell, said, "The pieces are quickly coming together as we demonstrate the advantages of our proprietary formulation and deliver it on a state-of-the-art stent with the lowest strut thickness commercially available. Our scalable drug and polymer coating process serves as a platform for the development of innovative interventional cardiology systems."

Dr. Kandzari is the Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, CA.

About Micell Technologies Inc.

Micell Technologies is a privately-held, development-stage biomedical device company dedicated to developing innovative interventional cardiology systems. By applying its unique surface and polymer modification technologies, Micell can precisely and consistently control drug elution and the duration of polymer exposure creating the potential for a therapeutic solution for coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Its first product in development, MiStent(TM), is a rapid absorbing coated drug-eluting stent with precise control of drug release and pharmacokinetics. Visit us at www.micell.com.

    Contact: Micell Technologies

    Arthur J. Benvenuto, Chairman & CEO
    (919) 313-2104


'/>"/>
SOURCE Micell Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Micell Rapid Absorption Polymer DES System to be Presented at TCT 2008
2. Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a fully-integrated ... of two long-standing principal investigators (PI) to the roles of Chief Medical Officer, ... , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, will ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a research registry built on the secure online PatientCrossroads platform, has exceeded both ... 1,600 participants have joined the PROMPT study, which seeks to advance understanding of ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... current winner of the Highest Overall Customer Rating Award from Circuits Assembly ... its business units across the USA, Canada, Mexico and China. , The EMS ...
(Date:2/9/2016)... ... February 08, 2016 , ... ... services, announced today the launch of its revamped and improved website. In an ... service solutions, the redesigned website will better communicate how the company designs and ...
Breaking Biology Technology:
(Date:2/2/2016)... YORK , Feb. 2, 2016 Technology Enhancements ... presents an analysis of the digital and computed radiography ... Malaysia , and Indonesia ... trends and market size, as well as regional market ... country and discusses market penetration and market attractiveness, both ...
(Date:2/1/2016)... -- Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of a new ... Las Vegas , where Joey appeared at the ... Las Vegas , where Joey appeared at the Wocket booth to ... was filmed at the Consumer Electronics Show (CES2016) in Las ... and greet fans. --> --> ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
Breaking Biology News(10 mins):